This website uses cookies to enhance the user experience.
S

SCIENCONS AS913 262 123

Research
Limited company
Kjelsåsveien 168 0884 OSLO, Norge

SCIENCONS AS

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Organization

Chairman of the board
Years since formation
10 years
since Mar 11, 2014
Type
Limited company
VAT registered
Yes
Number of employees
0

Ownership

Number of shares and share classes
100,000
1 share class
Total number of shareholders
1
person
Belongs to group of

Financials

Total operating income 2023
6,667
NOK
Annual total result 2023
11,693,144
NOK
Total equity 2023
45,064,492
NOK
Last update: Sep 26, 2024

Management

Management / administration

NameRoleShares
Managing Director/CEO
100 %
directly

Board

NameRoleShares
Chairman
100 %
directly

Others

NameRoleShares
R
REVISORKOLLEGIET AS
Auditor-

Top 10 individual shareholders

NameRoleShares
Managing Director/CEO, Chairman
100 %
directly
Last update: Apr 13, 2023

Ownership

Company shareholders

NameShare classNumber of sharesShare
Ordinary shares
100,000
100 %

Shares owned by the SCIENCONS AS

NameShare classNumber of sharesShare
N
NUCLITHERA AS
Ordinary shares
100,000
80 %
S
SRB RADIOPHARMA HOLDING AS
Ordinary shares
177,280
59.09 %
O
ONCOINVENT ASA
NO0010779341
3,217,223
16.59 %
T
THOR MEDICAL ASA
NO0010597883
2,000,000
0.86 %
NO0010358484
30,000
0.02 %
O
ORKLA ASA
NO0003733800
2,000
< 0.01 %
N
Norsk Hydro ASA
NO0005052605
400
< 0.01 %
K
KONGSBERG AUTOMOTIVE ASA
NO0003033102
500
< 0.01 %
I
IDEX BIOMETRICS ASA
NO0003070609
12,000
< 0.01 %
A
AKER BP ASA
NO0010345853
200
< 0.01 %
N
NORWEGIAN AIR SHUTTLE ASA
NO0010196140
20
< 0.01 %
D
DNB BANK ASA
NO0010161896
100
< 0.01 %
E
EUROPRIS ASA
NO0010735343
300
< 0.01 %
Last update: May 24, 2024

Group structure

  • Total operating income 2023: NOK 6,667
    Operating profit 2023: NOK -510,432
    Employees: 0

Financials

in NOK

Summary

Year202320222021
Total operating income
6,667
2,457,625
69,000
Annual Total Result
11,693,144
1,577,720
3,901,928
Total assets
51,939,939
40,664,586
38,477,357
Total liabilities
6,875,448
7,293,239
6,683,730
Total equity
45,064,492
33,371,347
31,793,627

P&L

Year202320222021
Total operating income
6,667
2,457,625
69,000
Total operating costs
517,099
713,805
738,203
Operating result
-510,432
1,743,820
-669,203
Financial income/costs
12,203,576
-166,100
4,571,131
Profit before tax
11,693,144
1,577,720
3,901,928
Total tax & extraordinary income/cost
0
0
0
Annual Total Result
11,693,144
1,577,720
3,901,928

Balance overview

Year202320222021
Total fixed assets
8,800,065
26,105,727
26,511,375
Total current assets
43,139,874
14,558,859
11,965,982
Total assets
51,939,939
40,664,586
38,477,357
Short term debt
243,512
661,304
55,303
Long term debt
6,631,936
6,631,935
6,628,427
Total liabilities
6,875,448
7,293,239
6,683,730
Contributed capital
3,341,944
3,341,944
3,341,944
Retained earnings
41,722,548
30,029,403
28,451,683
Total equity
45,064,492
33,371,347
31,793,627
Total equity and liabilities
51,939,939
40,664,586
38,477,357

Classification

Category
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
M
Main industrial area
Professional, scientific and technical activities
72
Activity
Scientific research and development
72.1
Main industrial group
Research and experimental development on natural sciences and engineering
72.11
Industrial group
Research and experimental development on biotechnology
72.110
Industrial group
Research and experimental development on biotechnology